Mark J. Rosenblum
Chairman and Chief Executive Officer
As On December 11, 2017, Mr. Rosenblum joined our Company as Chief Executive Officer and Chairman of the Board. Most recently Mark has consulted with mid-market companies that were public or “soon to be public”. Prior, Mark was the CFO of several publicly traded life science companies including Urigen Pharmaceuticals, Inc., a company developing innovative products to ameliorate the cause and symptoms associated with urological ailments, where he revamped the company’s financial processes and regained the company’s current status with the Securities and Exchange Commission . At Advaxis, Inc. ( NASDAQ: ADXS), a clinical development stage biotechnology company focused on the discovery, development and commercialization of Lm-LLO immunotherapies to treat cancers and infectious diseases where Mark was instrumental in renegotiating all the company’s debt, avoiding bankruptcy, and raising additional capital. Mark’s entrance to the life science space was as the Chief Financial Officer of Hemobiotech, Inc., a public company primarily engaged in the commercialization of human blood substitute technology.
For over 18 years, Mr. Rosenblum was employed by Wellman, Inc. (NYSE:WLM) now DAK Americas), a public chemical manufacturer and plastics recycling company. Mark joined the company in as Corporate Controller and grew to the role of Chief Accounting Officer. During Mark’s tenure Wellman grew from about $100 million in revenue to over $1billion as both the company’s core PET plastic recycling programs (i.e. soft drink bottles) and the explosion of overall PET container market (i.e. water bottles, all clear plastic containers) grew. As a member of the executive leadership team, Mark participated in acquisitions in Ireland, The Netherlands and several U.S. based companies that were downstream users of the company’s fiber and resin manufacturing businesses. Whilst the market for its PET resins grew, the market for its fibers slowed, Mark was responsible for the divestiture of several non-core businesses.
Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree (Accounting) from the University of South Carolina. Mr. Rosenblum is a member of the American Institute of Certified Public Accountants and was a licensed Certified Public Accountant for over 30 years.
During College, Mark. Rosenblum was a scholarship athlete and a two time captain of the men’s tennis team. Additionally, Mark was an interim head coach of the Gamecocks women’s tennis team for one season before starting his career in New York City with Haskins and Sells CPA’s (now Deloitte).
Executive Vice President and Director
Mr. Peterson has been constantly involved in numerous early stage ventures in the public and private sectors, with an emphasis in healthcare and technology while assisting such companies in advisory and investment initiatives. He has been our Vice President of Finance since July 2012. Before such time he served in various capacities within ActiveCare from July 2011 until July 2012. From January 2010 until July 2011 he was the Director of Investor Relations for SecureAlert. Prior to SecureAlert, Jeffery was a co-owner of Alpine Securities, a stock brokerage firm in Utah, where his roles included Broker, Market Maker, Communications Officer and AML Officer, while holding the following FINRA security licenses: 7, 63, 55, and 24. Jeffrey graduated from the University of Utah with a Bachelor of Arts Degree in Finance and Business Administration, while also being a founding member of the University Venture Fund. In addition to being Vice President of Finance, Jeffery is also a member of the Board of Directors and currently holds board observatory seats with Juneau Biosciences and CoNextions Medical.